BioLineRx (BLRX) Equity Ratio (2014 - 2025)
BioLineRx (BLRX) recorded quarterly Equity Ratio of 0.44 in Q4 2025, up 28.57% quarter-over-quarter from 0.35 in Q4 2024, and up 28.57% on a YoY basis from 0.35 in Q4 2024.
BioLineRx (BLRX) Equity Ratio (2014 - 2025) Analysis & Trends
BioLineRx's Equity Ratio history runs 9 years deep, the most recent figure standing at 0.44 for Q4 2025.
- In Q4 2025, Equity Ratio rose 28.57% year-over-year to 0.44; the TTM figure through Dec 2025 stood at 0.44 (up 28.57% YoY), while the FY2025 annual figure was 0.44, up 28.57% from the prior year.
- Equity Ratio was 0.44 for Q4 2025 at BioLineRx, up from 0.35 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.44 in Q4 2025 to a low of 0.35 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 191.07 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.98 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 0.04 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.42 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.73 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 0.79 |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | 0.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.44 |
| Dec 31, 2024 | 0.35 |
| Dec 31, 2020 | 0.47 |
| Dec 31, 2019 | 0.62 |
| Dec 31, 2018 | 0.73 |
| Dec 31, 2017 | 0.87 |
| Dec 31, 2016 | 0.90 |
| Dec 31, 2015 | 0.93 |
| Dec 31, 2014 | 0.88 |